Juvensis Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Juvensis Therapeutics - overview
Established
2021
Location
Shanghai, -, China
Primary Industry
Biotechnology
About
Based in Shanghai, China, and founded in 2021, Juvensis Therapeutics operates as a gene therapy product developer. In March 2025, Juvensis Therapeutics closed a pre-series A funding led by new investor Guofang Fund Management, with participation from other new investors Huntbest Capital, Nanjing Jiangbei New Area Sci-Tech Investment Group, Shanghai Industrial Investment, Summer Capital and returning investor GP Capital. The company has built a new generation telomere precision modulation technology platform to focus on unmet clinical needs such as heart failure. It has developed the telomere protection protein that can block the vicious cycle of telomere damage and mitochondrial dysfunction, thus promoting the recovery of myocardial function.
The company generates revenue by providing gene therapy products and in vitro cellular products business. The company will use the funds to advance the clinical development of its core cardiac gene therapy pipeline, JV101, and expand research into heart failure indications.
Current Investors
Blue Bay Capital, GP Capital, Shanghai Industrial Investment
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Juvensis Therapeutics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.